Table 4 Bivariable associations between standard dose dabigatran eligible patients’ characteristics on low or standard dose of dabigatran
| Standard dose eligible that received low dose Dabigatran (n = 1013) | Standard dose eligible that received standard dose Dabigatran (n = 5621) | P value | Before Matching Standardized Difference | After Matching (N = 1001 vs 1001) Standardized Difference | |
|---|---|---|---|---|---|
| Year | < 0.001 | ||||
| 2010–12 | 50.0% | 55.7% | 0.116 | 0.198 | |
| 2013 | 18.6% | 13.6% | 0.137 | 0.174 | |
| 2014 | 11.6% | 11.4% | 0.008 | 0.032 | |
| 2015 | 10.9% | 10.1% | 0.026 | 0.047 | |
| 2016–17 | 9.0% | 9.3% | 0.009 | 0.040 | |
| Region | 0.8 | ||||
| Midwest | 12.3% | 12.9% | 0.017 | 0.024 | |
| Northeast | 1.7% | 1.5% | 0.018 | 0.016 | |
| South | 73.7% | 74.3% | 0.012 | 0.009 | |
| West | 12.2% | 11.4% | 0.027 | 0.006 | |
| Age Category | < 0.001 | ||||
| 65–69 | 6.7% | 18.7% | 0.365 | 0 | |
| 70 to 74 | 12.5% | 27.3% | 0.3755 | 0 | |
| 75 to 79 | 19.0% | 24.9% | 0.143 | 0 | |
| 80 to 84 | 26.4% | 17.9% | 0.206 | 0 | |
| 85 to 89 | 18.5% | 6.9% | 0.351 | 0 | |
| 90 or over | 17.0% | 4.4% | 0.415 | 0 | |
| Sex | < 0.001 | ||||
| Female | 55.6% | 46.8% | 0.176 | 0 | |
| Male | 44.4% | 53.2% | |||
| Race Category | < 0.001 | ||||
| White | 84.0% | 87.9% | 0.113 | 0 | |
| Black | 10.1% | 6.6% | 0.126 | 0 | |
| Hispanic | 2.5% | 1.6% | 0.059 | 0 | |
| Asian | 1.2% | 0.6% | 0.066 | 0 | |
| Other | 2.3% | 3.3% | 0.060 | 0 | |
| Smoker | 15.0% | 16.8% | 0.15 | 0.049 | 0.037 |
| Weight Category (based on ICD-9/ ICD-10 codes for BMI) | 0.003 | ||||
| Under Weight | 1.1% | 0.6% | 0.057 | 0.031 | |
| Healthy or Overweight | 10.8% | 8.3% | 0.082 | 0.013 | |
| Obese or Severe Obese | 20.0% | 23.4% | 0.084 | 0.054 | |
| Others | 68.1% | 67.6% | 0.010 | 0.061 | |
| Comorbid Conditions | |||||
| Prior Stroke | 26.9% | 23.9% | 0.04 | 0.067 | 0.011 |
| Prior Major Bleeding | 25.8% | 23.9% | 0.2 | 0.044 | 0.042 |
| Diabetes | 48.9% | 48.0% | 0.6 | 0.018 | 0.066 |
| Prior AMI | 6.9% | 5.0% | 0.01 | 0.082 | 0.103 |
| Liver Disease | 3.6% | 2.5% | 0.07 | 0.059 | 0.126 |
| Heart Failure | 45.0% | 29.7% | < 0.001 | 0.320 | 0.274 |
| Hypertension | 95.1% | 93.0% | 0.01 | 0.089 | 0.088 |
| Ischemic Cardiomyopathy | 53.4% | 46.4% | < 0.001 | 0.140 | 0.110 |
| Pulmonary Circulatory Disease | 15.6% | 11.0% | < 0.001 | 0.135 | 0.083 |
| COPD | 35.7% | 31.0% | 0.003 | 0.1 | 0.115 |
| Blood Transfusion | 3.2% | 2.4% | 0.18 | 0.044 | 0 |
| Revascularization | 16.8% | 14.5% | 0.05 | 0.063 | 0.075 |
| Implantable cardiac device | 15.5% | 13.1% | 0.04 | 0.068 | 0.011 |
| Valve Disease | 44.1% | 40.0% | 0.015 | 0.083 | 0.024 |
| Concurrent Drugs (+/− 90 days of initiating DOAC) | |||||
| SSRI/SNRI | 34.0% | 30.0% | 0.01 | 0.085 | 0.126 |
| Strong and moderate p-gp inhibitors | 7.3% | 12.9% | < 0.001 | 0.188 | 0.135 |
| Warfarin | 19.9% | 24.0% | 0.004 | 0.099 | 0.237 |
| Strong p-gp and cyp3a4 dual inhibitors | 17.0% | 18.2% | 0.3 | 0.0325 | 0.032 |
| ACE inhibitors | 68.4% | 67.2% | 0.45 | 0.0257 | 0.081 |
| Angiotensin receptor blockers | 38.6% | 38.1% | 0.8 | 0.0094 | 0.010 |
| Beta blockers | 90.7% | 88.4% | 0.03 | 0.0759 | 0.108 |
| Calcium channel blockers | 65.5% | 63.2% | 0.15 | 0.0488 | 0.040 |
| Digoxin | 32.1% | 28.7% | 0.03 | 0.0741 | 0.002 |
| Proton pump inhibitors | 58.7% | 55.2% | 0.04 | 0.0707 | 0.008 |
| NSAIDs | 48.3% | 50.4% | 0.2 | 0.0433 | 0.04 |
| Antiplatelets | 30.5% | 25.7% | 0.0015 | 0.1064 | 0.093 |
| Insulin | 14.5% | 12.1% | 0.03 | 0.072 | 0.137 |
| Statins | 79.1% | 78.7% | 0.8 | 0.009 | 0.079 |
| Renal Disease | < 0.001 | ||||
| None or Mild | 33.6% | 57.2% | 0.489 | 0.255 | |
| Moderate (GFR 30–60 ml/min/1.73 m2) | 66.4% | 42.8% | |||
| Severe (GFR < 30 ml/min/1.73 m2) | 0.0% | 0.0% | |||